BerryC, McMurrayJ.A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics1999; 16: 247–71.
2.
McMurrayJJ, StewartS.Epidemiology, aetiology, and prognosis of heart failure. Heart2000; 83: 596–602.
3.
HoKKL, AndersonKM, KannelWB, GrossmanW, LevyD.Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation1993; 88: 107–15.
4.
McDonaghTA, MorrisonCE, LawrenceA.Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet1997; 350: 829–33.
5.
McMurrayJV, McDonaghTA, DavieAP, ClelandJGF, FrancisCM, MorrisonC.Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?Eur Heart J1998; 19: 842–6.
The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991; 325: 293–302.
8.
The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med1987; 316: 1429–35.
9.
PackerM, Poole-WilsonPA, ArmstrongPW.Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation1999; 100: 2312–8.
10.
GargR, YusufS, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA1995; 273: 1450–5.
11.
PackerM, BristowMR, CohnJN.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med1996; 334: 1349–55.
12.
Cardiac Insufficiency Bisoprolol Study II trial group.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999; 353: 9–13.
13.
HjalmarsonA, GoldsteinS, FagerbergB.Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA2000; 283: 1295–302.
14.
McMurrayJJ.Major beta blocker mortality trials in chronic heart failure: a critical review. Heart1999; 82 Suppl 4: IV14–22.
15.
PittB, ZannadF, RemmeWJ.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med1999; 341: 709–17.
16.
The Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med1997; 336: 525–33.
17.
WatsonRDS, GibbsCR, LipGYH.ABC of heart failure: clinical features and complications. BMJ2000; 320: 236–9.
18.
DavieAP, MacMurrayJJ.ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians?Postgrad Med J1999; 75: 219–22.
19.
McCollA, RoderickP, GabbayJ, SmithH, MooreM.Performance indicators for primary care groups: an evidence based approach. BMJ1998; 317: 1354–60.
20.
StewartS, PearsonS.Uncovering a multitude of sins: medication management in the home post acute hospitalisation among the chronically ill. Aust NZ J Med1999; 29: 220–7.
21.
LeiderHL.Heart failure and disease management. Am J Manag Care1998; 4(6 Suppl): S343–8.
RichMW, BeckhamV, WittenbergC, LevenCL, FreedlandKE, CarneyRM.A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med1995; 333: 1190–5.
24.
StewartS, MarleyJE, HorowitzJD.Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet1999; 354: 1077–83.
25.
JaarsmaT, HalfensR, Huijer A-SH.Effects of education and support on self-care and resource utilization in patients with heart failure. Eur Heart J1999; 20: 673–82.
26.
CampbellRL, BannerR, Konick-McMahanJ, NaylorMD.Discharge planning and home follow-up of the elderly patient with heart failure. Nurs Clin North Am1998; 33: 497–513.
27.
PittB, SegalR, MartinezFA.Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet1997; 349: 747–52.
28.
McKelvieRS, YusufS, PericakD.Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. Circulation1999; 100: 1056–64.
29.
PittB, Poole-WilsonPA, SegalR.Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet2000; 355: 1582–7.
30.
CohnJN, TognoniG, GlazerRD, SpormannD, HesterA.Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, and angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail1999; 5: 155–60.
31.
SwedbergK, PfefferM, GrangerC.Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail1999; 5: 276–82.
